Takeda Pharmaceutical Co ADR (TAK) concluded trading on Wednesday at a closing price of $13.24, with 4.79 million shares of worth about $63.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.08% during that period and on January 08, 2025 the price saw a loss of about -0.82%. Currently the company’s common shares owned by public are about 3.17B shares, out of which, 3.17B shares are available for trading.
Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of -3.57%. Year-to-date (YTD), TAK shares are showing a performance of 0.00% which decreased to -10.72% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.57 but also hit the highest price of $15.08 during that period. The average intraday trading volume for Takeda Pharmaceutical Co ADR shares is 1.66 million. The stock is currently trading -0.19% below its 20-day simple moving average (SMA20), while that difference is down -2.10% for SMA50 and it goes to -3.50% lower than SMA200.
Takeda Pharmaceutical Co ADR (NYSE: TAK) currently have 3.17B outstanding shares and institutions hold larger chunk of about 5.17% of that.
The stock has a current market capitalization of $41.98B and its 3Y-monthly beta is at 0.54. PE ratio of stock for trailing 12 months is 21.96, while it has posted earnings per share of $0.60 in the same period. Its PEG reads 0.63 and has Quick Ratio of 0.77 while making debt-to-equity ratio of 0.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TAK, volatility over the week remained 0.93% while standing at 1.04% over the month.
Stock’s fiscal year EPS is expected to drop by -12.71% while it is estimated to increase by 74.04% in next year. EPS is likely to grow at an annualized rate of 35.03% for next 5-years, compared to annual growth of -12.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on March 16, 2023 offering a Buy rating for the stock and assigned a target price of $20 to it. Coverage by Cowen stated Takeda Pharmaceutical Co ADR (TAK) stock as an Outperform in their note to investors on July 19, 2022, suggesting a price target of $24 for the stock. Stock get a Market perform rating from Cowen on November 01, 2019.
